WEEKLY 005 · EDITION RECORD
Combination development, AI-enabled trials and context-dependent cerebellar learning: three readings and an insight into how enabling work is rewarded.
Commercialization
AstraZeneca's investment in Summit is part of a wider pattern: companies are combining drugs, delivery methods and other capabilities—and choosing different ways to share the value.
R&D Allocation
SURPASS will fund the practical testing of AI-enabled clinical trial infrastructure. The commercial opportunity may lie in delivering a trial that works—not necessarily in owning the drug being tested.
Frontier Science
A study of mouse cortex and cerebellum asks how the brain preserves a shared pattern of experience while keeping different tasks apart.
This issue’s insight: How should we pay for the work that makes a treatment possible? →
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Linked approval; uptake and payment open
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
Institutional report; independent verification open
ART function remains unknown. The article compares experimental services, joint discovery and contractual options exercised after validation.
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
AstraZeneca announced a $2 billion Summit investment and ADC combinations. Other examples include weekly HIV regimens, temporary antibody reduction before gene therapy, and NK-cell/antibody combinations in autoimmunity.
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference.
The archive stores complete article text, public evidence references, event dates, scheduled/observed distinctions, topic states and disclosed series. It contains no mailbox identifiers or private email bodies.
Editorial record window: 2026-10-08 — 2026-10-09 / Method: editorial-events-v1